Phase II clinical trial - Appareil Digestif
DS8201-A-U207 DESTINY CRC02
Appareil Digestif
Ouvert depuis le: 12.11.2023
Site: Saint-Cloud
Public cible
Adulte
A Phase 2, Multicenter, Randomized, Study of Trastuzumab Deruxtecan in Participants With HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer (DESTINY-CRC02)
Description de l'essai
This study will evaluate the efficacy, safety, and pharmacokinetics of Trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor 2 (HER2)-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC).
Liens utiles